Key Finding
Cancer patients receiving heat-sensitive moxibustion with chemotherapy achieved a 50% tumor response rate compared to 28% with chemotherapy alone, while experiencing significantly reduced side effects including nausea, vomiting, and bone marrow suppression.
A recent Chinese study examined whether heat-sensitive moxibustion could help reduce side effects and improve treatment outcomes for cancer patients undergoing chemotherapy. Researchers followed 104 patients with malignant tumors over four chemotherapy cycles. Half received standard chemotherapy and medications, while the other half also received daily moxibustion treatments for one week before and after each chemotherapy session.
The results showed significant benefits for patients who received moxibustion. These patients experienced fewer adverse reactions overall, had better appetite scores, and suffered less nausea and vomiting compared to those receiving only standard care. Blood test results were notably better in the moxibustion group, showing higher white blood cell counts, hemoglobin levels, and platelet counts, indicating less bone marrow suppression—a common and serious side effect of chemotherapy. Perhaps most importantly, the moxibustion group showed a 50% tumor response rate compared to just 28% in the control group, suggesting the treatment may enhance chemotherapy's cancer-fighting effectiveness.
Heat-sensitive moxibustion is a traditional Chinese medicine technique that involves burning dried mugwort herb near specific points on the body. This study suggests it may offer meaningful support for cancer patients by reducing chemotherapy's harsh side effects while potentially improving treatment outcomes. The daily treatments appeared safe and well-tolerated throughout the study period. For patients considering moxibustion as part of their cancer care, it's essential to work with a qualified, licensed acupuncturist experienced in oncology support.
This randomized controlled trial evaluated heat-sensitive moxibustion as adjuvant therapy during chemotherapy in 150 malignant tumor patients (104 completed). The experimental group (n=54) received daily moxibustion for one week pre- and post-chemotherapy over four cycles, plus standard care. Controls (n=50) received standard chemotherapy and pharmacological treatment only. The moxibustion group demonstrated statistically significant improvements across multiple parameters: reduced incidence of adverse reactions (P<0.05-0.01), higher A/CS-12 appetite/cachexia scores (P<0.01), decreased nausea/vomiting rates (P<0.05-0.01), and less bone marrow suppression (P<0.05-0.01). Hematological markers showed superior white blood cell counts and hemoglobin levels before cycles 2-4 (P<0.05-0.01), with higher platelet counts before cycles 3-4 (P<0.01). RECIST 1.1 evaluation revealed significantly higher tumor response rates in the experimental group (50% vs 28%, P<0.05). Clinical implications suggest heat-sensitive moxibustion offers meaningful supportive care during chemotherapy, reducing toxicity while potentially enhancing antitumor efficacy.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Acupuncture significantly improved total sleep time by approximately 30 minutes and sleep efficiency by 4.56% compared to control groups in breast cancer patients with systemic therapy-associated insomnia.
📌 Cognitive behavioral therapy and hypnosis have the strongest evidence for reducing vasomotor symptoms in breast cancer survivors, while acupuncture may provide modest benefit as an adjunctive nonpharmacological treatment option.
📌 Traditional acupuncture reduced hot flash and night sweat frequency by nearly 50% in breast cancer survivors taking tamoxifen, with sustained effects lasting at least 18 weeks after treatment ended.